Recent Updates
-
Updated on: Dec 07, 2022
New Features of SOAPware 2011
Manual Clinical 2011 User Manual -
Updated on: Dec 07, 2022
NQF 0047 - (Additional) Asthma Pharmacologic Therapy
Measure: NQF 0047
Measurement Title: Asthma Pharmacologic Therapy
Measure Description: Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long‐term control medication (inhaled corticosteroid) or an acceptable alternative treatment.
*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL QM MEASURE: Click here to view Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0089 - (Additional) Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
Measure: NQF 0089 (Additional Measurement)
Measure: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
Measure Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.
*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0088 - (Additional) Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
Measure: NQF 0088 (Alternate Core Measurement)
Measure Title: Diabetic Retinopathy: Documentation of presence or absence of macular rdema and level of Severity of Retinopathy
Measure Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.
*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0083 (Additional) Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
Measure: NQF 0083 (Additional Measure)
Measure Title: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
Measurement Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were prescribed beta-blocker therapy.
*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0086 - (Additional) Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
Measure: NQF 0086 (Additional Measurement)
Measure Title: Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
Measure Description: Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least 2 office visits, who have an optic nerve head evaluation during one or more office visits within 12 months.
*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
(DRAFT) *NQF 0105 - (Additional) Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
THIS LESSON IS CURRENTLY A DRAFT AND IS NOT YET COMPLETE.
Measure: NQF 0105 (Additional Measurement)
Measure: Anti-depressant medication management: (a) Effective Acute Phase Treatment, (b)Effective Continuation Phase Treatment
Measure Description: The percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment.
*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
NQF 0031 (Additional): Breast Cancer Screening
Measure: NQF 0031 (Additional Measure)
Measure Title: Breast Cancer Screening
Measure Description: Percentage of women 40-69 years of age whom had a mammogram to screen for breast cancer
*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL CQM MEASURE: Click here to view Meaningful Use Criteria.
-
Updated on: Dec 07, 2022
Record of Disclosures
This lesson will demonstrate the necessary steps to meet the Meaningful Use requirement for Record of Disclosures.
*Note: Please download the following Templates into the database first, before proceeding with these steps.......Search using the following keywords: payment, treatment, and health care ops.
Manual Clinical 2011 User Manual -
Updated on: Dec 07, 2022
NQF 0067 (Additional) Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
Measure: NQF 0067
Measure Title: Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
Measure Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.
*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL CQM MEASURE: Click here to view Meaningful Use Criteria.